ALF Academic Debates

Thank you to our Participating Advocates: Alexion, Dova, Northwestern, and FUJIFILM Wako

Thank you to our Judges, Dr. Nikhil Bhargava, Dr. Sheila Eswaran, and Dr. Rocky Yapp

Thank you to Loyola Medicine Mentor, Dr. Jamie Berkes, and Fellows, Dr. Laura Nunez-Herrero and Dr. Irfan Rahman

Thank you to University of Illinois Mentor, Dr. Adam Mikolajczyk and Fellows, Dr. Wasseem Skef and Dr. Mitali Agarwal

Loyola Medicine will argue that TARE should be the primary locoregional therapy for unresectable HCC

The University of Illinois will argue, TACE should be the primary locoregional therapy for unresectable HCC

The final debate tonight asks, is TACE or TARE prefearble in patients with unresectable HCC?

Thank you to our Partner Advocates: Bayer, CVS, Eisai, Novartis, & Salix

Thank you to the Cook County Fellows, Dr. Alexander Nguyen & Dr. Efe Aisien

Thank you to the Cook County Mentor, Dr. Bashar Attar

Thank you you to the University of Iowa fellows, Dr. James Vancura & Dr. Jagpal Klair

That you to the University of Iowa mentor Dr. Arvind Murali

Cook County Health will argue the Con position that all patients with immune tolerant HBV do not need to be treated

University of Iowa will argue that all patients with immune tolerant HBV should be treated

The Hepatitis Topic is, "Should patients with immune tolerant Hepatitis B be treated?"

Thank You to our Premier Advocates: Abbvie, Gilead, and Intercept

Thank you to the University of Chicago Fellows: Dr. Jennifer Wang & Dr. Parita Patel

Thank you to University of Chicago's Mentor, Dr. Anjana Pillai

Thank you to Northwestern Medicine's Mentor, Dr. Priya Maddur

Thank you to the Northwestern Medicine Fellows: Dr. Alex Lemmer & Dr. Hersh Shroff